ASPAC III Acquisition Corp. announces $200M all-stock acquisition of Bioserica International

ASPAC III Acquisition Corp.

Agrees to acquire Bioserica International, a bio-based antimicrobial materials company, for $200M in stock at $10.00/share.
Transaction structured as reincorporation merger of SPAC into new BVI company, then merger with Bioserica.
Closing conditions include SEC registration effectiveness, SPAC shareholder approval, and Nasdaq listing.
Termination right if audited financials not delivered by May 31, 2025.
Agreement is subject to negotiation of definitive agreements; shares to be issued at $10.00 per Purchaser share.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.